References
- Gahery-Segard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, Tartar A, Levy JP, Gras-Masse H, Guillet JG: Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol 74;1694-1703, 2000 https://doi.org/10.1128/JVI.74.4.1694-1703.2000
- Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melamoma. Nat Med 4;321-327, 1998 https://doi.org/10.1038/nm0398-321
-
Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W: The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-
${\gamma}$ ELISPOT assays. J Immunol Methods 259;95-110, 2002 https://doi.org/10.1016/S0022-1759(01)00499-9 - Cai Z, Brunmark A, Jackson MR, Loh D, Peterson PA, Sprent J: Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells. Proc Natl Acad Sci USA 93;14736-14741, 1996
-
Janetzki S, Song P, Gupta V, Lewis JJ, Houghton AN: Insect cells as HLA-restricted antigen-presenting cells for the IFN-
${\gamma}$ ELISPOT assay. J Immunol Methods 234;1-12, 2000 https://doi.org/10.1016/S0022-1759(99)00203-3 - Latouche JB, Sadelain M: Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 18;405-409, 2000 https://doi.org/10.1038/74455
- Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH: Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20;143-148, 2002 https://doi.org/10.1038/nbt0102-4
- Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL: A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and longterm growth of CD4 T lymphocytes. Clin Immunol 105;259-272, 2002 https://doi.org/10.1006/clim.2002.5277
- Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45;321-334, 1975
- Garson D, Dokhelar MC, Wakasugi H, Mishal Z, Tursz T:HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: modulation by differentiation inducers and interferon. Exp Hematol 9; 885-890, 1985
- Drew SI, Terasaki PI, Billing RJ, Bergh T, Huber C, Erfle V, Rieber P, Theobald M, Sutter G: Group-specific human granulocyte antigens on a chronic myelogenous leukemia cell line with a Philadelphia chromosome marker. Blood 49;715-718, 1977
- Saksela E, Timonen T, Ranki A, Hayry P: Morphological and functional characterization of isolated effector cells responsible for human natural killer activity to fetal fibroblasts and to cultured cell line targets. Immunol Rev 44;71-123, 1979 https://doi.org/10.1111/j.1600-065X.1979.tb00268.x
- Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-William MG, Bell JI, McMichael AJ, Davis MM: Phenotypic analysis of antigen specific T lymphocytes. Science 274;94-96, 1996 https://doi.org/10.1126/science.274.5284.94
-
Britten CM, Meyer RG, Frnakenberg N, Huber C, Wolfer T:The use of clonal mRNA as an antigenic format for the detection of antigen-specific T lymphocytes in IFN-
${\gamma}$ ELISPOT assays. J Immunol Methods 287;125-136, 2004 https://doi.org/10.1016/j.jim.2004.01.026 -
Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini JC, Woelfel T, Eggermont AMM, Keilholz U:Qunatitation of antigen-reactive T cells in peripheral blood by IFN
${\gamma}$ -ELISPOT assay and chromium-realease assay: a four-centre comparative trial. J Immunol Methods 244;81-89, 2000 https://doi.org/10.1016/S0022-1759(00)00257-X - Romero P, Cerottini JC, Waanders GA: Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol Med 4;305-312, 1998
-
Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, Naeher H, Rammensee HG, Keilholz U: Analysis of the T cell response to tumor and viral peptide antigens by an IFN
${\gamma}$ -ELISPOT assay. Int J Cancer 71;932-936, 1997 https://doi.org/10.1002/(SICI)1097-0215(19970611)71:6<932::AID-IJC3>3.0.CO;2-Z - Kim JV, Latouche JB, Riviere I, Sadelain M: The ABCs of artificial antigen presentation. Nat Biotechnol 22;403-410, 2004 https://doi.org/10.1038/nbt955
- Dupont J, Latouche JB, Ma C, Sadelain M: Artificial antigenpresenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 65;5417-5427, 2005 https://doi.org/10.1158/0008-5472.CAN-04-2991
-
Griffioen M, Borghi M, Schrier PI, Osanto S: Detection and quantification of CD8+ T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-
${\gamma}$ -ELISPOT assay. Int J Cancer 93;549-555, 2001 https://doi.org/10.1002/ijc.1361 - Guelly C, Kupcu Z, Zalusky D, Karner M, Zehetner M, Schweighoffer T: Activation requirements of circulating antigenspecific human CD8+ memory T cells probed with insect cell-based artificial antigen-presenting cells. Eur J Immunol 32;182-192, 2002 https://doi.org/10.1002/1521-4141(200201)32:1<182::AID-IMMU182>3.0.CO;2-P
- Zhang HG, Pang XW, Shang XY, Xing Q, Chen WF:Functional supertype of HLA-A2 in the presentation of Flu matrix p58-66 to induce CD8+ T-cell response in a Northern Chinese population. Tissue Antigens 62;285-295, 2003 https://doi.org/10.1034/j.1399-0039.2003.00102.x
- Cho HI, Han H, Kim CC, Kim TG: Generation of cytotoxic T lymphocytes specific for human cytomegalovirus using dendritic cell in vitro. J Immunother 24;242-249, 2001 https://doi.org/10.1097/00002371-200105000-00008
- Sette A, Sidney J: HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol 10;478-482, 1998 https://doi.org/10.1016/S0952-7915(98)80124-6
- Sentman CL, Barber MA, Barber A, Zhang T: NK cell receptors as tools in cancer immunotherapy. Adv Cancer Res 95;249-292, 2006 https://doi.org/10.1016/S0065-230X(06)95007-6